Provided are indole derivative compounds of the general formula (I), where the variables are as defined in the specification. Examples of the compounds include (2R,3S,4S)-1-[2-(3-Acetyl-indol-1-yl)-acetyl]-3,4-difluoro-pyrrolidine-2-carboxylic acid 3-chloro-2-fluorobenzylamide, (2S,5R)-5-Methyl-pyrrolidine-1,2-dicarboxylic acid 1-[(1-carbamoyl-1 H-indol-3-yl)-amide] 2-(3-chloro-2-fluoro-benzylamide) and 2-({ [(2S,4R)-1-(1-Carbamoyl-1H-indol-3-ylcarbamoyl)-4-fluoro-pyrrolidine-2-carbonyl]-amino} -methyl)-benzoic acid. A particularly preferred compound is 1-(2-((1R,3S,5R)-3-((6-bromopyridin-2-yl)carbamoyl)-2-azabicyclo[3.1.0]hexan-2-yl)-2-oxoethyl)-1H-indazole-3-carboxamide. The compounds modulate Factor D of the complement system. The compounds may be useful in the treatment of ophthalmic, autoimmune, respiratory and cardiovascular diseases. The compounds may be particularly useful in the treatment of age-related macular degeneration (AMD).
